CompletedNot Applicable

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.

Russia184 participantsStarted 2018-11-07

Plain-language summary

One-center, observational, non-interventional, prospective study of the efficacy of azilsartan medoxomil in patients with arterial hypertension associated with stable ischemic heart disease and type 2 diabetes mellitus.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Informed consent signed by the patient.
✓. Men and women aged 18 years and older with a previously diagnosed hypertension and type 2 diabetes mellitus and stable ischemic heart disease.
✓. Stable therapy of hypertension, T2DM and ischemic heart disease for at least 12 weeks before screening.
✓. Not achievement of target values \* of blood pressure against the background of previously prescribed and steadily accepted antihypertensive therapy.
✓. Investigator's decision on the advisability of correction of previously prescribed therapy with the replacement of ACE inhibitors or other ARBs with azilsartan medoxomil.

Exclusion criteria

✕. Contraindications to the azilsartan medoxomil in accordance with instruction for use, including information on the individual intolerance of the drug.
✕. Any circumstances in the opinion of the investigator that interfere with the participation of the patient in the study.
✕. The patient included in the study is an employee of the center or a relative of the investigator.
✕. Participation in other clinical trials. Participation in register studies is allowed.
✕. Any disease or condition that leads to a decrease in the patient's life expectancy.

What they're measuring

Systolic blood pressure

Timeframe: interval: up to 24 weeks

Trial details

NCT IDNCT03539627

SponsorResearch Institute for Complex Problems of Cardiovascular Diseases, Russia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-29

View on ClinicalTrials.gov More Arterial Hypertension trials